It is prevailingly thought that estrogen signaling is not involved in development of estrogen receptor (ER)-negative breast cancer. However, there is evidence indicating that ovariectomy prevents the development of both ER-positive and -negative breast cancer, suggesting that estrogen signaling is involved in the development of ER-negative breast cancer. Previously, our laboratory cloned a variant of ER-a, ER-a36, and found that ER-a36 mediated nongenomic estrogen signaling and is highly expressed in ER-negative breast cancer cells. In this study, we found that ER-a36 was highly expressed in 10/12 cases of triple-negative breast cancer. We investigated the role of mitogenic estrogen signaling mediated by ER-a36 in malignant growth of triple-negative breast cancer MDA-MB-231 and MDA-MB-436 cells that express high levels of ER-a36 and found that these cells strongly responded to mitogenic estrogen signaling both in vitro and in vivo. Knockdown of ER-a36 expression in these cells using the small hairpin RNA method diminished their responsiveness to estrogen. ER-a36 physically interacted with the EGFR/Src/Shc complex and mediated estrogen-induced phosphorylation of epidermal growth factor receptor (EGFR) and Src. EGFR signaling activated ER-a36 transcription through an AP1 site in the ER-a36 promoter, and ER-a36 expression was able to stabilize EGFR protein. Our results, thus demonstrated that ER-a36 mediates nongenomic estrogen signaling through the EGFR/Src/ERK signaling pathway in ERnegative breast cancer cells and suggested that a subset of ER-negative breast tumors that expresses ER-a36, retains responsiveness to mitogenic estrogen signaling.
Introduction
Estrogen receptor (ER)-negative breast cancer constitutes B30% of all the breast cancers and generally is more aggressive than ER-positive breast cancer (Lacroix et al., 2004; Simpson et al., 2005) . Because of the lack of ER-a expression, it is prevailingly thought that estrogen signaling is not involved in development and progression of ER-negative breast cancer. However, several early reports showed that ovariectomy prevents formation of both ER-positive and -negative breast cancers (Nissen-Meyer, 1964; Early Breast Cancer Trialists' Collaborative Group, 1992) . Interestingly, BRCA1-mutation-related breast tumors, the vast majority of which are ER-negative, are also effectively prevented by prophylactic ovariectomy (Rebbeck et al., 1999; Narod, 2001 ). These observations suggested that ovarian hormones contribute to development of ER-negative breast cancers. Previously, it was reported that estrogen activates the PI3K/AKT phosphorylation in ER-negative breast cancer cells (Tsai et al., 2001) . Estrogen treatment was reported to stimulate malignant growth of ER-negative breast cancer MDA-MB-231 cells in immunodeficient mice (Friedl and Jordan, 1994) . These results suggested that some ER-negative breast cancer cell lines may retain nongenomic and mitogenic estrogen signaling. However, the molecular mechanisms underlying these observations are largely unknown.
Previously, we identified and cloned a 36 kDa variant of ER-a, ER-a36, which is mainly expressed on the plasma membrane and mediates nongenomic estrogenic signaling (Wang et al., 2005 (Wang et al., , 2006 . ER-a36 lacks both transcription activation domains AF-1 and AF-2 of the 66 kDa full-length ER-a (ER-a66), and possesses an altered ligand-binding domain and an intact DNAbinding domain, consistent with the fact that ER-a36 has no intrinsic transcriptional activity but mediates nongenomic estrogen signaling (Wang et al., 2006) . ER-a36 is generated from a promoter located in the first intron of the ER-a66 gene (Zou et al., 2009) , indicating that ER-a36 expression is regulated differently from ER-a66, consistent with the findings that ER-a36 is expressed in specimens from ER-negative patients and established ER-negative breast cancer cells that lack ER-a66 expression (Wang et al., 2006; Lee et al., 2008; Shi et al., 2009 ).
We have investigated the contribution of nongenomic estrogen signaling mediated by ER-a36 to malignant growth of ER-negative breast cancer cells. Here, we have demonstrated the existence of a positive feedback loop between ER-a36 and epidermal growth factor receptor (EGFR) expression, and a cross talk between nongenomic estrogen signaling mediated by ER-a36 and the EGFR/Src/ERK signaling pathway, which promotes malignant growth of ER-negative breast cancer cells.
Results

Nongenomic estrogen signaling stimulates proliferation of ER-negative breast cancer cells
Here, we examined ER-a36 expression in 12 cases of triple-negative breast cancer (ER-a66À, PRÀ and Her2/ neuÀ) and found that 10 out of the 12 cases exhibited ER-a36 expression, predominantly in a cytoplasmic and membranous pattern (Supplementary Figure 1) . The mean percentage of the ER-a36-positive cells was 53% and the majority of the cases showed weak to moderate ER-a36 staining. EGFR expression was detected in six cases, four of which coexpressed ER-a36. These results suggested that a subset of triple-negative breast cancer lacks expression of the full-length ER-a (ER-a66) but expresses a variant of ER-a66, ER-a36.
To determine whether established triple-negative breast cancer cells that express ER-a36 retain nongenomic estrogen signaling, we used breast cancer MDA-MB-231 and MDA-MB-436 cells, both of which are triple-negative. Western blot analysis showed that both ER-a36 and EGFR are highly expressed in these breast cancer cells, whereas ER-positive MCF7 cells expressed high levels of ER-a66 but lower levels of ER-a36 and EGFR ( Figure 1a) .
To determine whether 17b-estradiol (E2b) induced phosphorylation of the MAPK/ERK1/2, a typical nongenomic estrogen-signaling event, in these two cell lines, we treated cells with E2b at different concentrations and for different time periods. Western blot analysis with a phospho-specific ERK1/2 antibody was performed. Figure 1b shows that E2b elicited ERK phosphorylation in both cell lines in a dose-dependent manner starting at a extremely low concentration, 1 Â 10 À16 M/l. Time course analysis in MDA-MB-231 cells revealed that ERK phosphorylation occurred within 5 min after E2b application, peaked at 15 min, declined at 30 min and then exhibited another more sustained activation at 60 min. However, this doublepeak induction pattern of the MAPK/ERK was not obvious in MDA-MB-436 cells (Figure 1b) . Consequently, E2b was also able to induce expression of the growth-promoting genes c-Myc and cyclin D1 in both cell lines (Figure 1c ). These results demonstrated that these triple-negative breast cancer cells retained nongenomic estrogen signaling.
We then decided to determine whether estrogen stimulates proliferation of these triple-negative breast cancer cells. As these triple-negative breast cancer cells express high levels of EGFR, which makes these cells proliferate at a near-maximal rate in serum-supplemented medium, the stimulating effects of estrogen signaling on proliferation of these cells are, most of the time, too subtle to detect in vitro in the presence of 10-5% fetal calf serum (Friedl and Jordan, 1994; Rai et al., 2005) . To alleviate this problem, we devised a new strategy by reducing charcoal-stripped fetal calf serum concentration from 10 to 2.5% and increased estrogen treatment time to 12 days. As shown in Figure 1d , the cells treated with E2b exhibited a significantly increased growth rate compared with cells treated with vehicle ( Figure 1d ). Our data thus demonstrated that mitogenic estrogen signaling stimulates proliferation of these ER-negative breast cancer cells.
ER-a36 mediates mitogenic estrogen signaling in ER-negative breast cancer cells To determine whether ER-a36 mediates mitogenic estrogen signaling in these breast cancer cells, we designed two small hairpin RNA (shRNA) expression vectors targeting different regions of the 3 0 UTR of ERa36 and established two clonal cell lines from MDA-MB-231 cells that express these two different shRNAs. MDA-MB-231 cells transfected with an empty expression vector or an expression vector for shRNA against firefly luciferase were used as controls. Both western blot analysis and reverse transcriptase PCR demonstrated that ER-a36 expression was knocked-down about 80% in the shRNA-expression vector-transfected cells compared with control cells (Figure 2a ). E2b treatment failed to induce ERK1/2 phosphorylation, expression of c-Myc and cyclin D1, and cell proliferation in MDA-MB-231 cell lines with knocked-down level of ER-a36 expression (Figures 2b and c) . Similar results were also observed in MDA-MB-436 cells with knockeddown levels of ER-a36 expression (Figures 2d-g ). However, serum was still able to induce ERK activation in MDA-MB-436 cells with knocked-down level of ERa36 expression (Figure 2e ), indicating there was no defect of the MAPK/ERK signaling in cells with ERa36 expression knocked down. These results demonstrated that ER-a36 mediates nongenomic and mitogenic estrogen signaling in these ER-negative breast cancer cells.
Previously, ER-negative breast cancer MDA-MB-231 cells were found to express ER-b, a subtype of ER (Tong et al., 2002) . Western blot analysis showed that MDA-MB-231 cells express higher levels of ER-b compared with ER-positive MCF7 cells, whereas MDA-MB-436 cells express undetectable levels of ER-b (Supplementary Figure 2A ). To determine whether ER-b is involved in the estrogen effects observed in MDA-MB-231 cells, we knocked-down ER-b expression in MDA-MB-231 cells with transient transfection of ER-b small interfering RNA (siRNA). The estrogen effects, such as activation of the MAPK/ERK and stimulation of cell proliferation, were intact and even with a slight increase (Supplementary Figures 2B-D) , suggesting that ER-b may negatively regulate mitogenic estrogen signaling mediated by ER-a36.
To assess the effect of estrogen signaling on the tumorigenicity of these cells, two MDA-MB-231 cell lines with knocked-down levels of ER-a36 expression and a control cell line transfected with the empty expression vector were inoculated subcutaneously into the fat pad of ovariectomized female nude mice. At 5 days before inoculation, mice were implanted with E2b or placebo pellets. In two independent experiments, tumors were readily detected at all sites injected with vector-control cells in the absence and presence of estrogen supplement (Figure 3a) . However, the tumors that formed in the presence of estrogen developed more rapidly than their counterparts without estrogen. Additionally, MDA-MB-231 cells with knocked-down level of ER-a36 expression failed to form tumors in the absence of estrogen, whereas formed tumors less efficiently compared with control cells in the presence of estrogen (Figure 3a) . Our results were in good agreement with the previous report that estrogen was able to stimulate malignant growth of MDA-MB-231 cells in vivo (Friedl and Jordan, 1994) .
To test whether the tumor-enhancing effects of estrogen extended to weak tumorigenic breast cancer cells, we repeated the above experiment with MDA-MB-436 cells. The vector-control MDA-MB-436 cells formed palpable mammary tumors in about 6 weeks in the absence of estrogen. In contrast, the vectorcontrol cells in the supplement of estrogen formed tumor with higher efficiency and a significant shorter latency, arising 2-3 weeks before their counterparts without estrogen. MDA-MB-436 cells with knockeddown level of ER-a36 expression did not form tumors in the absence of estrogen, even in a prolonged incubation (20 weeks), whereas developed tumors with much less efficiency in the presence of estrogen. These experiments demonstrated estrogen stimulated malignant growth of these ER-negative breast cancer cells in vivo.
EGFR protein is stabilized by ER-a36 in ER-negative breast cancer cells
The finding that ER-a36 downregulation dramatically suppresses the tumorigenicity of these ER-negative breast cancer cells in the absence of estrogen was surprising as these cells also express high levels of EGFR, which would promote malignant growth in vivo. To elucidate the underlying mechanisms, western blot analysis was performed to examine the expression levels of EGFR protein in the cells with ER-a36 expression knocked down. Figure 4a shows that expression levels of EGFR protein were dramatically decreased in MDA-MB-231 cell lines with ER-a36 expression knockeddown compared with control cells. However, we did not observe significant change in the mRNA levels of EGFR in these cells, suggesting that the steady state levels of EGFR protein were decreased in ER-a36 knockeddown MDA-MB-231 cells (Figure 4a) . A similar destabilization of EGFR protein was also observed in MDA-MB-436 cells with knocked-down levels of ERa36 expression (Figure 4b) . Western blot analysis further demonstrated that on treatment with MG132, a proteasome inhibitor, the levels of EGFR protein in the ER-a36 knocked-down cells were restored to levels comparable with those of control cells (Figure 4c ), indicating that the protein degradation of EGFR was enhanced in ER-a36 downregulated cells. Thus, ER-a36 is involved in regulation of the steady-state levels of EGFR protein.
EGFR signaling upregulates ER-a36 expression
Recently, we cloned the promoter region of ER-a36 and identified that ER-a36 promoter harbors several Ap-1 binding sites (Zou et al., 2009) , suggesting that ER-a36 expression may be subjected to regulation of the growth factor signaling pathways. To determine whether EGFR signaling influences ER-a36 expression, we treated both cell lines with the PI3K inhibitor LY294002, EGFR inhibitors BiBx, AG1478 and Gefitinib, and the Src inhibitor PP2. Figure 5a shows that treatment with the EGFR inhibitors strongly downregulated ER-a36 expression at both protein and mRNA levels in both cell lines, whereas the PI3K inhibitor LY294002 had no effect. Our data thus suggested that ER-a36 transcription is subjected to positive regulation by EGFR signaling.
To examine whether EGFR signaling directly upregulates ER-a36 promoter activity, we performed cotransfection assays in human embryonic kidney (HEK) 293 cells that express no detectable levels of both ER-a36 and EGFR. HEK-293 cells were transiently transfected with a luciferase reporter plasmid driven by the ER-a36 promoter (Zou et al., 2009) . EGFR co-transfection resulted in an about 3-fold induction of ER-a36 promoter activity, which was blocked by pretreatment of the EGFR inhibitor AG1478 and Gefitinib, and the Src inhibitor PP2, but not by the PI3K inhibitor LY294002 (Figures 5b and c) . When a series of 5 0 truncated promoter of ER-a36 ( Figure 5b ) was used, we found that EGFR expression failed to activate the promoter activity of the pER36-513 .5% dextran-charcoal-stripped fetal calf serum were treated with indicated concentrations of E2b or ethanol vehicle as a control. The cell numbers were determined using an automatic cell counter after 12 days. Five dishes were used for each concentration and experiments were repeated more than four times. The mean cell numbers±s.e. are shown.
reporter plasmid (Figure 5b ). Close examination of DNA sequence in the deleted region revealed an AP-1-binding site located between À541 and À551 (relative to the transcription initiation site) residues of the ER-a36 promoter region (Figure 5b ). Mutation of this Ap-1 site abrogated induction of ER-a36 promoter activity by EGFR co-transfection (Figure 5b ), suggesting that EGFR signaling activated ER-a36 promoter activity through the EGFR/Src/ ERK1/2/AP-1 pathway.
ER-a36 interacts with the EGFR complex and mediates E2b-induced phosphorylation of Src and EGFR To elucidate the molecular mechanism underlying ERa36 functions, we examined whether ER-a36 interacts with the EGFR complex. MDA-MB-231 cells were transiently transfected with an expression vector for HA-tagged ER-a36 and coimmunoprecipitation assays were performed with cell lysates from transfected cells. Figure 6a shows that EGFR, Src and Shc coexisted in the immunoprecipitates of the anti-HA antibody. We also noticed that the levels of EGFR in the immunoprecipitates were slightly decreased after E2b treatment, whereas the levels of Shc and Src were increased (Figure 6a) . In MDA-MB-436 cells, interaction between EGFR and ER-a36 was also observed in the absence of E2b. After treatment of E2b for 1 h, ER-a36 was gradually dissociated from the EGFR and associated with Src and Shc (Figure 6b) .
We also examined changes of the phosphorylation levels of EGFR with different phospho-specific antibodies against different residues of EGFR, including Tyr-845, Tyr-992, Tyr-1045, Tyr-1068 and Tyr-1173 in MDA-MB-231 cells in the presence and absence of E2b. We found that Tyr-845 was the only residue that was phosphorylated after E2b application (Supplementary Figure 3) and E2b elicited a transient increase of EGFRTyr-845 phosphorylation; started at 5 min and declined at 30 min (Figure 6c ). The E2b-induced phosphorylation was totally abrogated by the Src inhibitor PP2 but partially blocked by the EGFR inhibitor AG1478 (Figures 6c and d) , consistent with the previous report that Src phosphorylates EGFR at Tyr-845 (Biscardi et al., 1999) . We also observed that E2b treatment induced phosphorylation of Src at Tyr-416 (Figure 6c) , which was totally blocked by the Src inhibitor PP2 but partially by the EGFR inhibitor AG1478 (Figure 6d) , consistent with the activation pattern of the MAPK/ ERK by E2b (Figure 6d ). These results indicated that the EGFR/Src/Shc complex is involved in transduction of the nongenomic estrogen signaling mediated by ER-a36.
Discussion
In this report, we found that 10 out of the 12 cases of triple-negative breast cancer expressed ER-a36, predominantly on the plasma membrane and in the cytoplasm. EGFR expression was detected in six cases, four of which coexpressed ER-a36, which indicated that a subset of triple-negative breast cancer coexpresses ERa36 and EGFR. We then used MDA-MB-231 and MDA-MB-436 cells as models to study the effects of the nongenomic estrogen signaling mediated by ER-a36 on the malignant growth of ER-negative breast cancer.
Here, we found that ER-negative breast cancer cells that lack expression of ER-a66 but express ER-a36 exhibited a potent mitogenic estrogen signaling in vitro and in vivo. Previously, other laboratories failed to observe estrogen-stimulated growth of MDA-MB-231 cells in vitro (Friedl and Jordan, 1994; Rai et al., 2005) but found stimulatory effects of estrogen in vivo (Friedl and Jordan, 1994) . One possible explanation to the discrepancy between their data and ours is that the in vitro proliferation experiments by these laboratories were conducted in phenol-red-free medium supplemented with 10-5% charcoal-treated fetal calf serum and assayed in 7 or 8 days, which made MDA-MB-231 cells that express high levels of EGFR, to grow at a rapid rate in serum-supplemented medium. The stimulating effects of estrogen signaling on proliferation of these cells are negligible most of the time (Friedl and Jordan, 1994; Rai et al., 2005) . To minimize the growth rate of MDA-MB-231 cells, we used phenol-red-free medium containing 2.5% charcoal-treated serum (the minimum concentration that keeps MDA-MB-231 cell viable) and increased estrogen treatment time to 12 days in our growth assays. Under these conditions, we consistently observed potent growth promoting effects of estrogen on proliferation of these ER-negative breast cancer cells. It is worth noting that E2b also stimulated growth of the ER-negative endometrial carcinoma cells in athymic mice (Friedl et al., 1989) , consistent with our recent report that ERa36 is expressed in ER-negative endometrial carcinoma cells (Lin et al., 2010) .
Previously, ER-negative breast cancer cells were found to express ER-b receptor (Tong et al., 2002) . However, the role of ER-b in ER-negative breast cancer is largely unknown. Previous studies showed that ER-b inhibited proliferation of breast cancer cells by repressing c-myc and cyclin D1 (Lazennec et al., 2001; Paruthiyil et al., 2004; Behrens et al., 2007) . In this study, we used ER-b-specific siRNA to knock-down ER-b expression in MDA-MB-231 cells and found that cells with knocked-down levels of ER-b expression retained a full (or even increased) response to mitogenic estrogen signaling, suggesting that ER-b may negatively regulate ER-a36-mediated nongenomic estrogen signaling and that the inhibitory activities of ER-b may be also involved in failure of c-myc and cyclin D1 induction and loss of the tumorigenecity observed in MDA-MB-231 cells with knocked-down levels of ER-a36 expression.
In the present study, we also revealed a novel crosstalk mechanism in which EGFR and ER-a36 positively regulate each other's expression, which may play an important role in malignant growth of triple-negative breast cancer. We also showed that E2b induced the MAPK/ERK activation through a mechanism that involves ER-a36 and the EGFR/Src/Shc complex. We noted that ER-a36 interacted strongly with EGFR in the absence of estrogen, whereas interaction between ER-a36 and the Src/Shc was estrogen dependent, suggesting that ER-a36 may dynamically change its partners during estrogen signaling. We also found that E2b predominantly induced phosphorylation of the EGFR-Tyr-845 residue but not the major autophosphorylation sites of EGFR, such as Tyr-992, -1068 and -1073. EGFR Tyr-845 is a site phosphorylated by activated Src (Biscardi et al., 1999) . Consistent with this, we found that E2b also induced Src-Tyr-416 phosphorylation and the Src inhibitor PP2 blocked E2b-induced phosphorylation of Src-Tyr-416 and EGFR-Tyr-845, whereas the EGFR inhibitor AG1478 had less effect. Our results thus indicated that EGFR/ Src complex has an integral role in mitogenic estrogen signaling in ER-negative breast cancer cells that express ER-a36.
Clinical evidence established that ER-negative breast cancer is less or non-responsive to antiestrogen therapy, which would be at the odds with our finding that estrogen signaling is involved in malignant growth of ER-negative breast cancer cells. It is well known that tamoxifen acts as both agonist and antagonist. Recently, we found that ER-a36-mediated agonist action of tamoxifen in ER-negative endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways (Lin et al., 2010) . It is thus possible that ER-a36 may mediate tamoxifen agonist effects in the ER-negative breast cancer cells that express ER-a36. ICI 182780, a 'pure' antiestrogen, works by accelerating degradation of ERa66 protein (Howell et al., 2000) . Recently, we reported that ICI 182780 failed to induce degradation of ER-a36 (Kang and Wang, 2010) , presumably because ER-a36 has a truncated ligand-binding domain, which lacks the last four helices (helix 9-12) of ER-a66 (Wang et al., 2005) ; the helix-12 domain is critical in protein degradation induced by ICI 182780 (Mahfoudi et al., 1995) . This may provide a molecular explanation for the clinical evidence that these antiestrogens failed to inhibit growth of ER-negative breast cancer cells that express ER-a36. We also found that these ER-negative breast cancer cells responded to very low concentrations of estrogen; activation of the MAPK/ERK signaling was observed at 10 À16 M/l, suggesting that cells expressing high levels of ER-a36 are hypersensitive to estrogen. Thus, ER-negative breast cancer cell that expresses high levels of ER-a36 may be hypersensitive to estrogen, which may render this subset of breast cancer less sensitive to aromatase inhibitors that usually suppress the plasma level of E2b to a mean of picomolar range (Geisler et al., 2002) .
In summary, we have shown that ER-a36 expressing ER-negative breast cancer cells retained mitogenic responses to estrogen, suggesting that nongenomic estrogen signaling contributes to development and progression of ER-negative breast cancer cells that express ER-a36. Thus, ER-a36 is a novel player in mitogenic estrogen signaling, which may play important roles in mammary tumorigenesis and in other types of estrogen-related tumors as well.
Materials and methods
Chemicals and antibodies
The 17b-estradiol (E2b) was purchased from Sigma Chemical (St Louis, MO, USA). The MEK1/2 inhibitor U0126, the Src inhibitor PP2 and the PI3K inhibitor LY294002 were from Tocris Bioscience (Ellisville, MO, USA). The proteasome 0 truncated promoters of ER-a36. The À736, À584, and À513 indicate residues upstream of the transcription initiation site. An AP-1-binding site is also indicated that was mutated in the pER36-mAP1 plasmid. HEK-293 cells were transfected with different reporter plasmids together with an empty expression vector or an expression vector for EGFR. The luciferase activities were assayed and normalized using a cytomegalovirus-driven Renilla luciferase plasmid. Columns represent the means of four independent experiments; bars represent the s.e. *Po0.05 for cells transfected with the EGFR expression vector vs an empty expression vector. (c) HEK293 cells were transfected with the pER36-736 reporter plasmid with the empty expression vector or the EGFR expression vector and then treated with vehicle, 10 mM of LY294002, PP2, Gefitinib or AG1478 for 24 h. The luciferase activities were then normalized and analyzed. Results shown in graph are means from four experiments; bars, s.e. *Po0.05 for cells treated with vehicle vs under different conditions. inhibitor MG132, and the EGFR inhibitors BiBx and AG1478 were purchased from EMD Chemicals (Gibbstown, NJ, USA) and the EGFR inhibitor Gefitinib was from LC Laboratories (Woburn, MA, USA). Phospho-EGFR and -Src antibodies, EGFR, Src and Shc antibodies, anti-phospho-p44/42 ERK (Thr-202/Tyr-204) antibody and anti-p44/42 ERK antibody were all purchased from Cell Signaling Technology (Boston, MA, USA). Polyclonal anti-ER-a36 antibody was generated and characterized as described before (Wang et al., 2006) . Antibodies of c-Myc, ER-b and cyclin D1 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). ER-a66, HER-2/ Neu and progesterone receptor antibodies were obtained from Ventana Medical Systems (Tucson, AZ, USA). ER-b siRNA and control siRNA-A were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Specimen analysis and immunohistochemistry
A total of 12 formalin-fixed paraffin-embedded tumor samples of triple-negative breast carcinomas were retrieved from the collection of Clinical Center of the University of Sarajevo after approval of the Institutional Review Board. Immunohistochemical assay for ER-a36, ER-a66, progesterone receptor and EGFR expression were performed using the commercially available detection kits and automated staining procedures. Protein expression was scored according to the American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations (Wolff et al., 2007) .
Cell culture, treatment and growth assay MDA-MB-231, MDA-MB-436 cells and human embryonic kidney cell line (HEK293) were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). All parental and derivative cells were maintained in Dulbecco 0 s modied Eagle 0 s medium and 10% fetal calf serum at 37 1C in a 5% CO 2 incubator. For E2b treatment, cells were maintained in phenolred-free media with 2.5% charcoal-stripped fetal calf serum (HyClone, Logan, UT, USA) for 3 days and then in serum-free medium for 24 h before experimentation. To test the effects of different inhibitors, all inhibitors were added 10 min before the E2b addition. For the MG-132 treatment, 10 mM MG132 was added 12 h before cell harvest.
To cell growth assays, cells were treated with indicated concentrations of E2b or vehicle (ethanol) as a control. The cells were seeded at 1 Â 10 4 cells per dish in 60 mm dishes and the cell numbers were determined using the ADAM automatic cell counter (NanoEn Tek Inc., Seoul, Korea) after 12 days. Five dishes were used for each treatment and experiments were repeated more than three times.
Establishment of stable cell lines MDA-MB-231 and MDA-MB-436 cells with ER-a36 expression knocked down by the shRNA method were established as described before (Kang and Wang, 2010) . MDA-MB-231 cells transfected with the empty expression vector, a control vector expressing shRNA for luciferase or two different ER-a36-specific shRNA expression vector were named as 231/V, 231/ lucSh, 231/Sh36(3-1) and 231/Sh36(1-7), respectively. For MDA-MB-436 cells, cells transfected with the empty expression vector or the ER-a36 shRNA expression vector were selected for 3 weeks, and more than 20 clones of selected cells were pooled and named as 436/V and 436/Sh36. siRNA transfection MDA-MB-231 cells were seeded at 2 Â 10 5 cells/dish in 60 mm culture dishes 24 h before transfection. ER-b or control siRNA weighing 1 mg was mixed with siRNA transfetion medium and siRNA transfection reagent (Santa Cruz Biotechnology) and incubated for 30 min at room temperature before added into cultured cells. The efficiency of siRNA knock-down was assessed with western blot analysis.
RNA purification and reverse transcriptase-PCR Total RNA was prepared with the 'TRIzol' RNA purification reagent. Total RNA weighing 1 mg was reversely transcribed using the ProtoScript II RT-PCR kit (New England Biolab, Ipswich, MA, USA). Reverse transcriptase PCR analysis of ER-a36, EGFR and b-actin was performed using gene specific primers as the following. ER-a36-forward primer: 5 0 -CAAG TGGTTTCCTCGTGTCTAAAG-3 0 , reverse primer: 5 0 -TGT TGAGTGTTGGTTGCCAGG-3 0 ; EGFR-forward primer: 5 0 -CGTCCGCAAGTGTAAGAA-3 0 , reverse primer: 5 0 -AGC AAAAACCCTGTGATT-3 0 ; b-actin-forward primer: 5 0 -TG ACGGGGTCACCCACACTGTGCCCATCTA-3 0 , reverse primer: 5 0 -CTAGAAGCATTTGCGGTGGACGATGGAGG G-3 0 . PCR procedure was carried out as described before (Zou et al., 2009) . PCR products were analyzed by electrophoresis in a 1.5% agarose gel and visualized by ethidium bromide staining under ultraviolet illumination.
DNA mutagenesis
To mutate the AP-1 consensus-binding site from 5 0 -AGAGT CA-3 0 to 5 0 -AGctTCA-3 0 , the mutated primers ER-a36P-AP1 m forward: 5 0 -GCAGCCCGCGCTGCGTTCAGctTCA AGTTCTCTCGCCGGG-3 0 and reverse: 5 0 -CCCGGCGAGA GAACTTGAagCTGAACGCAGCGCGGGCTGC-3 0 were used. The mutagenesis was performed using the QuikChange II site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's protocol. The mutation was verified by DNA sequencing.
DNA transfection and luciferase assay HEK-293 cells were transfected using FuGene 6 transfection reagent (Roche Applied Science, Indianapolis, IN, USA) with the pER36-736-Luc, pER36-584-Luc, pER36-513-Luc or pER36-296-Luc reporter plasmids as described before (Zou et al., 2009) and an empty expression vector or the expression vector for EGFR (a kind gift from Dr Laura Hansen at Creighton University). Cells were co-transfected with a cytomegalovirus-driven Renilla luciferase plasmid, pRL-CMV (Promega, Madison, WI, USA) to establish transfection efficiency. At 24 h after transfection, cells were treated with vehicle, 10 mM of U0126, PP2, or LY294002 for 24 h. At 48 h after transfection, cell extracts were prepared and luciferase activities were determined and normalized using the DualLuciferase Assay System (Promega).
Immunoprecipitation and immunoblot analysis
For immunoprecipitation assays, cells were washed twice with ice-cold phosphate buffered saline and lysed with the lysis buffer (150 mM NaCl, 20 mM Tris-HCl, pH 7.4, 0.1% NP-40) supplemented with protease and phosphatase inhibitors (Sigma Chemical). Cell lysates were then incubated with indicated primary antibodies or pre-immune serum and immunoprecipitated with protein A/G plus agarose. The precipitates were then washed, separated on SDS-polyacrylamide gel electrophoresis and analyzed with western blot analysis as described before (Kang and Wang, 2010) .
Tumor formation in nude mice
Tumor formation was assayed using ovariectomized female nude mice (5-to 6-week old, strain CDI nu/nu, Charles River Laboratories International, Wilmington, MA, USA). ERnegative breast cancer cells maintained in phenol-red-free media with 2.5% charcoal-stripped fetal calf serum for 3 days were washed with 0.025% edetate sodium (Versene Dow, Midland, MI, USA) and 0.05% trypsin in a Ca 2 þ -and Mg 2 þ -free PBS before inoculation. For MDA-MB-231 cells, a total of 1 Â 10 6 cells for each clone were resuspended in 0.1 ml of PBS and inoculated subcutaneously into the mammary fat pad of ovariectomized female nude mice 5 days after subcutaneous implantation of 1.7 mg/60-day release of E2 (treated; 12 mice) or placebo (control; 12 mice) pellets (Innovative Research of American, Sarasota, FL, USA). Tumor growth was monitored by measuring two perpendicular diameters with vernier calipers. For MDA-MB-436 cells, 1 Â 10 6 cells for each cell line were resuspended in 0.1 ml Matrixgel Basement Membrane Matrix (BD Biosciences, San Jose, CA, USA) and inoculated into the fat pad of ovariectomized female nude mice. The estrogen and placebo pellets were replaced after 60 days. Tumor growth was measured weekly. Tumor volume based on caliper measurements were calculated by the formula: tumor volume ¼ 1/2(length Â width 2 ).
Statistical analysis
Data were summarized as the mean±s.e. using the GraphPad InStat software program (GraphPad Software, La Jolla, CA, USA). Tukey-Kramer multiple comparisons test was also used, and the significance was accepted for Po0.05.
